




Source MDx OncoProfilingSM Biomarker Services for Targeted Oncology Drug Development

Source MDx OncoProfilingSM Service Offerings Combine High Precision Gene Expression Analysis of Circulating Tumor and Endothelial Cells with over 1,000 RNA-based Oncology Gene Assays to Enhance Development of Targeted Cancer Therapies for Pharmaceutical and Biotechnology Companies including:

- **Source MDx Precision ProfilingTM Gene Expression** provides a molecular response of specific target genes of interest from a patient's whole blood, tumor tissue or circulating rare cell samples.
- **Circulating Tumor and Endothelial Cell Detection and Enumeration** provides for the capture and counting of rare circulating tumor and endothelial cells in peripheral whole blood using the Veridex CellSearch SystemTM.
- **Circulating Tumor and Endothelial Cell Capture and Enrichment** allows for the isolation and enrichment of circulating rare cells using the Veridex CellSearch SystemTM for additional culturing and further off-line analysis using high precision gene expression.
- **CTC Phenotyping** with tumor-specific antibodies provides a more directed approach for the development of cancer therapies.
- **In-vitro Drug Studies** provide key stimulus/drug response data using enriched and cultured circulating tumor and endothelial cells for off-line gene expression analysis.



Source MDx Oncology and Inflammation Gene Assays

The over 1,000 oncology genes selected by Source MDx for our rigorous technical and clinical validation process include genes reported in the scientific literature that play a role in specific types of cancer, as well as genes more generally linked to human cancer as follows:

- Source MDx has developed disease specific OncoProfiling panels of between 75 to 125 genes for breast, prostate, lung, colon, melanoma, cervical and ovarian cancer tumor tissues and whole blood gene expression analysis.
- Source MDx offers oncology gene assays for approximately 250 human general cancer genes including genes that play a role in angiogenesis, apoptosis and tumor progression and suppression.
- Source MDx offers approximately 300 gene assays including cytokines, chemokines and cell signaling that track inflammatory conditions and immune system response associated with cancer.
- Source MDx offers custom gene assay development with our same high standards of technical validation for our clients (based on a four to six week development time).
- Source MDx also offers custom development of its oncology gene assays for other species including mouse models as reverse engineered animal models (REAM studies) providing a molecular validation of cross species biomarkers.

Source MDx Technical Validation of Oncology Gene Assays


The over 1,000 RNA-based oncology gene assays each go through a custom primer/probe design and a technical validation process that yields precision and calibrated amplification forming the basis of the Source MDx Precision Profiles™. The Precision Profile assay is a multiplexed Polymerase Chain Reaction (PCR) assay optimized by Source MDx to measure the gene expression of a biological condition or agent in untreated and treated biological samples derived from body fluids (such as whole blood), tissues (such as tumors) or culture medium (such as keratinocytes and THP-1 cells). Total RNA is extracted from each sample and a first strand synthesis is performed using a reverse transcriptase (RT) to generate cDNA. The cDNA serves as a template for use in a Precision Profile assay where individual gene amplification is quantified by real-time Quantitative Polymerase Chain Reaction (QPCR) using the ABI Prism® 7900HT Sequence Detection System. Key to the Precision Profile Assay is the concept of precision and calibration (U.S. patent 6,692,916) achieved through proprietary reagents (target gene primer-probe sets), high performance plates (Precision Profile plates) and strict adherence to narrow permissible levels of experimental variables.

Source MDx Clinical Validation of Oncology Gene Assays


Source MDx now has oncology biomarker clinical trials in progress using the cancer specific gene assays described above in prostate, breast, colon, lung, melanoma, cervical and ovarian cancers including collaborations with leading academic cancer research centers including Dana-Farber Cancer Institute and the University of Colorado Health Sciences Center. The focus is on early detection of cancer, predictive biomarkers and responders and non-responders to drug therapy. We have already been granted molecular diagnostic patents on a breast cancer panel and a prostate cancer panel. In addition, the company has patents pending for molecular diagnostics panels for melanoma, colon cancer and lung cancer. Our pilot studies in these cancers have demonstrated the ability to distinguish cancer patients from healthy normal subjects with over 85% correct classification with small sets of between 2 and 6 genes. Larger validation studies are currently in progress to confirm these initial results. This biomarker and diagnostics development process assures our pharmaceutical clients that our OncoProfiling gene assays are undergoing rigorous clinical validation and are a cost effective and proven tool set to use in their Phase 1, 2 and 3 oncology clinical trials.

Source MDx Healthy Normals Oncology Reference Dataset

Foundational to all Source MDx biomarker and companion diagnostics development work is the reference to a Healthy Normals dataset for each of the over 1,000 oncology gene assays. A key requirement for clinical application of gene expression technology is distinguishing between natural variations in gene expression among healthy subjects and changes associated with cancer. Source MDx has been granted a patent regarding the establishment of a normal range of expression for a subject population as a "reference range" for molecular diagnostics (U.S. patent 6,960,439). Several key Source MDx discoveries are included in this issued patent and a science article featured in *Molecular Medicine*, July/August 2006. First, the dynamic range of expression of many genes is limited among healthy subjects; second, expression levels for most genes analyzed are approximately log-normally distributed; and third, tight regulation and homeostatic control of gene responses are fundamental characteristics of the immune system as reflected in the narrow range of expression levels and return to set points for key molecules in inflammatory/immune pathways among healthy subjects. Source MDx now routinely uses healthy normal reference ranges for gene expression assays, providing critical standards for the diagnosis and management of disease.



Benefits of Source MDx RNA OncoProfiling for the Drug Development Process



The Source MDx biomarker and companion diagnostic development process runs in parallel with the well-established drug development process and mirrors the FDA's stated position of early involvement of therapeutics and diagnostics in the co-development of companion diagnostics.

Source MDx Step 1: Biomarker R&D

- Define broad target gene panels (96 – 150 genes) by pathway or disease
- Design and validate custom primers and probes for each target gene
- Define healthy normals reference range in humans for each target gene

Source MDx OncoProfiling Benefits:

- Early integration of target gene panels in relevant pre-clinical study activities including
 - Cell-based assays
 - Whole blood assays
 - CTC enrichment assays
 - Methods development
 - Platform validation
 - Biomarker discovery validation

Source MDx Step 2: Biomarker Discovery by Disease

- Run pilot observational studies in active disease
 - Single time-point
 - Longitudinal tracking
- Run sub-population observational studies
- Build models that discriminate active disease from normals
- Define more focused target gene panels (24-48 genes)

Source MDx OncoProfiling Benefits:

- Identify disease biomarkers
- Stratify disease sub-populations by molecular data and clinical observations
- Correlate human target gene panels with species-specific target gene panels in animal studies
 - Standard animal model studies
 - Reverse engineered animal model (REAM) studies

Source MDx Step 3: Surrogate End-Point Validation

- Run Phase I and II clinical trials tracking disease progression and response to therapy
- Define clinical panels (3-10 genes) for Phase III studies

Source MDx OncoProfiling Benefits:

- Measure escalating dose response
- Enrich cohort populations
- Confirm drug wash-out
- Monitor for adverse effects, including over suppression of the immune system
- Track therapeutic response using a
 - Treat-to-normal strategy and
 - Identify responders from non-responders
- Validate biomarkers with surrogate clinical end-points
- Provide data to support new patent filings or extension of existing filings

Source MDx Companion Diagnostics for Targeted Cancer Therapy

Industry observers predict that oncology will be an early area for successful predictive biomarkers and companion diagnostics tests to distinguish responders vs non-responders to therapy. Companion diagnostics are a by-product of the application of Source MDx's proven tool set for acceleration of the drug development process. Source MDx provides a proven tool set for biomarker development in every phase of this process from pre-clinical to clinical (Phase 1, 2 and 3), including companion diagnostic tests protected by a foundational patent portfolio. A proven tool set that is tightly integrated in pre-clinical and clinical activities provides a targeted approach with greater confidence at each progressive step of the development process. For pharmaceutical clients, this translates to a substantial return on investment by having common tools at the pre-clinical and clinical levels to make quicker and more definitive decisions regarding compound development. Furthermore, better targeted therapies with diagnostic tools to stratify populations, allows for FDA approval of drugs that work well in a segment of the population that may otherwise be rejected as a blockbuster drug.



Source MDx Assesses the Molecular Status of Cancer Patients through State-of-the-Art Characterization of Circulating Tumor and Endothelial Cells

The Source MDx OncoProfiling gene expression services allow our clients to research the molecular differences of over 1,000 oncology related genes for both tumors and circulating tumor cells and track individual response to therapy from a patient's whole blood, tumor tissue or circulating rare cell samples. Clinical trials have confirmed the importance of CTCs as key predictors of survival in certain cancers such as breast cancer. Source MDx's unique cell biology capabilities will provide pharmaceutical and biotech companies with a more targeted approach to development of cancer therapies, and allow a better understanding of the molecular differences and response to therapy of the primary tumor versus the metastasized cancer.

Source MDx's "Stick to Stat" Oncology Services include:

- Consultation in clinical trial protocol design and development maximizing the use of Veridex's CellSearch System™ with Source MDx's proprietary RNA-based molecular diagnostics proven toolset.
- Clinical site training in the proper acquisition, storage and transfer of:
 - whole blood samples in PAXgene™ Blood RNA tubes or Tempus™ tubes
 - biopsy tissue or biofluid samples in lysis buffer
 - CTC/CEC samples in CellSave® preservative tubes
- Clinical site sample tracking and quality monitoring.
- Custom primer/probe design and validation.
- Circulating tumor and endothelial cell detection, and enumeration or capture and enrichment.
- RNA stabilization, processing and quality control from whole blood, tissue and other biofluid samples as well as enriched rare cell samples.
- High precision gene expression using real-time Quantitative PCR.
- Sophisticated statistical modeling to interpret gene expression data in the context of a "normal range" with additional correlation to clinical outcomes.
- Custom data interpretation and reporting.

Veridex CellSearch System™ The Source MDx OncoProfiling service combines CellSearch System™ technology, from Veridex, LLC, with Source MDx's proprietary RNA-based molecular diagnostics toolset. The Veridex CellSearch System™ is designed to semi-automate and standardize the capture, enrichment, identification and enumeration of circulating tumor cells (CTCs) and circulating endothelial cells (CECs) in peripheral blood.

Source MDx has completed over 150 preclinical and clinical projects for more than 30 pharmaceutical and biotechnology companies. The commercial laboratory is equipped with state-of-the-art technology including the Veridex CellSearch System™ and the ABI Prism® 7900HT Sequence Detection System suite of instruments. Source MDx laboratory processes follow strict standard operating procedures and maintain high standards of quality control regardless of throughput. Source MDx also supports pharmaceutical company core labs seeking to outsource the processing and analysis of in-house pre-clinical and clinical sample overflow that meet their own internal standards of quality.

Business Development & Services

Jim Walther
VP Business Development
p 303-385-2705
e jim.walther@sourcemdx.com

Media

Michelle Linn
p 508-419-1555
e linnmich@sourcemdx.com

Corporate Headquarters

2500 Central Avenue, Suite H2
Boulder, CO 80301
p 303-385-2700
f 303-385-2750
www.sourcemdx.com

Boston Office

Karl Wassmann
CEO & President
199 Wells Avenue, Suite 209
Newton, MA 02459
p 617-244-5508
e karl.wassmann@sourcemdx.com